Adaptimmune

We are working to redefine the treatment of some of the most challenging types of cancer.

For Patients. For Practioners. For the Future.

Join Us

The personal nature of our science and our drive is supported by the perseverance to successfully discover, develop and commercialize cell therapies.

The personal nature of our science and our drive is supported by the perseverance to successfully discover, develop and commercialize cell therapies.

Our drive is to redefine how some of the most challenging-to-treat solid tumors are treated. Our proprietary cell therapy platform engineers a patient’s own cells to fight cancer.

With our robust pipeline of cell therapies, our goal is to, one day, significantly improve the patient’s treatment experience across a variety of solid tumor cancers.

Adaptimmune embraces this personalized approach from discovery through delivery with fully integrated capabilities including research, global clinical development, translational sciences, commercialization, and manufacturing.

Company History

2023

  • BLA submission completed for afami-cel in synovial sarcoma to enable commercialization
    Click here to learn more.
  • Earlier line and CPI combo SURPASS cohorts initiated for head & neck and bladder cancers
  • SURPASS-3 Phase 2 trial initiated for ovarian cancer
  • Received transfer of IND for lete-cel program from GSK
    Click here to learn more.

2022

  • Rolling BLA submission initiated for afami-cel in synovial sarcoma
  • 52% ORR in ovarian, head & neck and bladder cancers reported during company update in SURPASS Phase 1 trial
    Click here to learn more.
  • US manufacturing facility expanded
  • Allogeneic manufacturing facility completes construction

2021

2020

  • SPEARHEAD-1 (afami-cel) pivotal trial in synovial sarcoma enrollment complete
  • Allogeneic platform: iPSC-derived iT-Cells reported at ASGCT to kill MAGE-A4 target cells.
    Click here to learn more.

2019

  • SPEARHEAD-1 (afami-cel) pivotal trial in synovial sarcoma initiated
  • SURPASS Phase 1 trial (ADP-A2M4CD8) in MAGE-A4 solid tumor indications initiated

2018

  • US T-cell manufacturing facility opened
  • UK vector manufacturing facility opened

2017

  • Completion of public offering with net proceeds of $61,397,000

2016

  • New UK HQ and R&D facility opened

2015

  • IPO and NASDAQ listing
  • First engineered TCR T-cell in the clinic (NY-ESO)